poisar

Stocks · News reference

Recursion Announces Alignment with FDA on Registrational Phase 3 Trial Design for REC-4881 in Familial Adenomatous Polyposis

Fiscal.ai

Recursion Pharmaceuticals has reached an agreement with the FDA on the design of its registrational Phase 3 clinical trial for REC-4881, an investigational oral MEK1/2 inhibitor for treating familial adenomatous polyposis (FAP).

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncCoherent Market Insights

    AI in Drug Discovery Market to Reach USD 15,536.2 Million by 2033 at 25.1% CAGR | Coherent Market Insights

    The global AI in drug discovery market is projected to grow from USD 3,240.0 million in 2026 to USD 15,536.2 million by 2033, with a CAGR of 25.1%. Growth is driven by increasing pharmaceutical investments in AI infrastructure, machine learning adoption, and collaborations between pharma companies and AI providers. North America leads with 51.6% market share, while Asia Pacific shows the fastest growth at 27.2% CAGR. Key trends include generative AI for molecule design, multimodal AI for biological data analysis, and growing focus on AI model validation.